DIR Return Create A Forum - Home
---------------------------------------------------------
MS Speaks
HTML https://msspeaks.createaforum.com
---------------------------------------------------------
*****************************************************
DIR Return to: TYSABRI (natalizumab)
*****************************************************
#Post#: 924--------------------------------------------------
(Abst.) Hematologic modifications in Tysabri-treated MS patients
By: agate Date: September 6, 2015, 7:44 pm
---------------------------------------------------------
From Neurology Neuroimmunology and Neuroinflammation (June
2015):
[quote]Hematologic modifications in natalizumab-treated multiple
sclerosis patients
An 18-month longitudinal study
Claire Bridel, MD, PhD*, Yan Beauverd, MD*, Kaveh Samii, MD and
Patrice H. Lalive, MD
From the Department of Clinical Neurosciences (C.B., P.H.L.),
Division of Neurology, Unit of Neuroimmunology and Multiple
Sclerosis; Department of Hematology (Y.B., K.S.); and Department
of Genetics and Laboratory Medicine (P.H.L.), Laboratory
Medicine Service, University Hospital of Geneva, Switzerland.
Objective:
To monitor the hematologic modifications in the peripheral blood
of patients with relapsing-remitting multiple sclerosis treated
with natalizumab.
Methods:
The cohort included 44 patients with relapsing-remitting
multiple sclerosis treated monthly with natalizumab for 18
months. Peripheral blood was collected before treatment
initiation and on a monthly basis during the treatment course.
Complete blood cell count was performed using automated
hematology systems. Blood smears were prepared and analyzed when
abnormal values were detected.
Results:
Mean total white blood cell, lymphocyte, and eosinophil counts
were significantly higher 1 month after treatment initiation and
remained stable during the 18 months of follow-up. Monocyte
counts increased progressively during the 18-month treatment
with natalizumab. Erythroblasts and neutrophil precursors were
absent before treatment initiation but were present in 16% and
6.8% of patients, respectively, 1 month after the first
natalizumab infusion. The proportion of patients with
erythroblasts and neutrophil precursors remained stable
throughout the 18-month follow-up period.
On an individual patient basis, a fluctuating level of
erythroblasts and neutrophil precursors was observed. No
difference in mean erythrocyte, hemoglobin, hematocrit,
thrombocyte, and neutrophil levels was observed before and after
18 months of natalizumab treatment. No cases of myelodysplastic
syndrome or acute leukemia were observed.
Conclusion:
Chronic treatment with natalizumab is associated with
significant modifications in complete blood cell count,
including emergence of hematopoietic precursors that are not
present in peripheral blood under normal conditions. None of
these modifications were associated with malignancy.[/quote]
The entire article is available here
HTML http://nn.neurology.org/content/2/4/e123.full?cid=MR-eJP-Society-AANHotTopics.
*****************************************************